Tamsulosin
Generic name: tamsulosin hydrochloride · Brand names: Flomax, Jalyn (combination product containing dutasteride and tamsulosin): NOT covered on this record
Quick facts
Drug class
Value
alpha1 adrenoceptor antagonist (alpha blocker)
Source
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display (Highlights: "Tamsulosin hydrochloride capsules are an alpha1 adrenoceptor antagonist indicated for treatment of the signs and symptoms of benign prostatic hyperplasia"); https://medlineplus.gov/druginfo/meds/a698012.html ("Tamsulosin is in a class of medications called alpha blockers.")
Rx or otc
Value
Rx
Source
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display (package label: "100 Capsules Rx only"; Product Type HUMAN PRESCRIPTION DRUG)
Controlled schedule
Source
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display
Forms and strengths
- Capsule: 0.4 mg are olive green opaque/orange opaque size ‘0’ hard gelatin capsules imprinted with ‘D’ on cap and ‘53’ on body with black edible ink filled with white to off-white beadlets.
Forms source
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display section 3
Generic available
Value
yes
Source
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display (Marketing Information: ANDA ANDA202433; Labeler Rising Pharma Holdings, Inc.)
Common use one line
Alpha blocker used to treat the signs and symptoms of benign prostatic hyperplasia (BPH, enlarged prostate).
What it is used for
Tamsulosin treats the signs and symptoms of benign prostatic hyperplasia (BPH). It is not indicated for the treatment of hypertension.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
1
Source text (exact source wording)
Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies (14)]. Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension.
How it works
BPH symptoms come from a blocked bladder outlet with a static part (larger prostate) and a dynamic part (tight smooth muscle). Blocking alpha1 adrenoceptors relaxes smooth muscle in the bladder neck and prostate, improving urine flow and reducing BPH symptoms. Tamsulosin is selective for alpha1 receptors in the human prostate.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
12.1 (first part)
Source text (exact source wording)
The symptoms associated with benign prostatic hyperplasia (BPH) are related to bladder outlet obstruction, which is comprised of two underlying components: static and dynamic. The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component is a function of an increase in smooth muscle tone in the prostate and bladder neck leading to constriction of the bladder outlet. Smooth muscle tone is mediated by the sympathetic nervous stimulation of alpha1 adrenoceptors, which are abundant in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockade of these adrenoceptors can cause smooth muscles in the bladder neck and prostate to relax, resulting in an improvement in urine flow rate and a reduction in symptoms of BPH.
Tamsulosin, an alpha1 adrenoceptor blocking agent, exhibits selectivity for alpha1 receptors in the human prostate.
Tamsulosin, an alpha1 adrenoceptor blocking agent, exhibits selectivity for alpha1 receptors in the human prostate.
Dosage: adults
The recommended dose is 0.4 mg once daily, taken about one-half hour after the same meal each day. Do not crush, chew or open the capsule. If there is no response after 2 to 4 weeks, the dose can be increased to 0.8 mg once daily. If treatment is stopped or interrupted for several days, restart at 0.4 mg once daily.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
2
Source text (exact source wording)
Tamsulosin hydrochloride capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. Tamsulosin hydrochloride capsules should not be crushed, chewed or opened.
For those patients who fail to respond to the 0.4 mg dose after 2 to 4 weeks of dosing, the dose of tamsulosin hydrochloride capsules can be increased to 0.8 mg once daily. Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Warnings and Precautions (5.2)].
If tamsulosin hydrochloride capsules administration is discontinued or interrupted for several days at either the 0.4 mg or 0.8 mg dose, therapy should be started again with the 0.4 mg once-daily dose.
For those patients who fail to respond to the 0.4 mg dose after 2 to 4 weeks of dosing, the dose of tamsulosin hydrochloride capsules can be increased to 0.8 mg once daily. Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Warnings and Precautions (5.2)].
If tamsulosin hydrochloride capsules administration is discontinued or interrupted for several days at either the 0.4 mg or 0.8 mg dose, therapy should be started again with the 0.4 mg once-daily dose.
Dosage: children
Tamsulosin is not indicated for use in pediatric populations. Two studies in patients 2 years to 16 years of age did not demonstrate efficacy and positive benefit/risk.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
8.4 (first two paragraphs)
Source text (exact source wording)
8.4 Pediatric Use
Tamsulosin hydrochloride capsules are not indicated for use in pediatric populations.
Efficacy and positive benefit/risk of tamsulosin hydrochloride was not demonstrated in two studies conducted in patients 2 years to 16 years of age with elevated detrusor leak point pressure (>40 cm H2O) associated with known neurological disorder (e.g., spina bifida).
Tamsulosin hydrochloride capsules are not indicated for use in pediatric populations.
Efficacy and positive benefit/risk of tamsulosin hydrochloride was not demonstrated in two studies conducted in patients 2 years to 16 years of age with elevated detrusor leak point pressure (>40 cm H2O) associated with known neurological disorder (e.g., spina bifida).
Dosage adjustments
Drug interaction caps
The 0.4 mg capsule should not be used with strong CYP3A4 inhibitors such as ketoconazole. Use caution with moderate CYP3A4 inhibitors, strong or moderate CYP2D6 inhibitors, CYP2D6 poor metabolizers and cimetidine, especially at doses higher than 0.4 mg (for example 0.8 mg).
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
2; 5.2
Source text (exact source wording)
2: Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Warnings and Precautions (5.2)].
5.2 Drug Interactions
Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6. Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. Tamsulosin hydrochloride capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
Tamsulosin hydrochloride capsules should be used with caution in combination with cimetidine, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
Tamsulosin hydrochloride capsules should not be used in combination with other alpha adrenergic blocking agents [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].
Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].
Caution should be exercised with concomitant administration of warfarin and tamsulosin hydrochloride capsules [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)].
5.2 Drug Interactions
Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6. Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. Tamsulosin hydrochloride capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
Tamsulosin hydrochloride capsules should be used with caution in combination with cimetidine, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
Tamsulosin hydrochloride capsules should not be used in combination with other alpha adrenergic blocking agents [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].
Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].
Caution should be exercised with concomitant administration of warfarin and tamsulosin hydrochloride capsules [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)].
Kidney
Patients with renal impairment do not need a dose adjustment. Patients with end-stage renal disease (CLcr<10 mL/min/1.73 m2) have not been studied.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
8.6
Source text (exact source wording)
8.6 Renal Impairment
Patients with renal impairment do not require an adjustment in tamsulosin hydrochloride capsules dosing. However, patients with end-stage renal disease (CLcr<10 mL/min/1.73 m2) have not been studied [see Clinical Pharmacology (12.3)].
Patients with renal impairment do not require an adjustment in tamsulosin hydrochloride capsules dosing. However, patients with end-stage renal disease (CLcr<10 mL/min/1.73 m2) have not been studied [see Clinical Pharmacology (12.3)].
Liver
Patients with moderate liver impairment do not need a dose adjustment. Tamsulosin has not been studied in patients with severe hepatic impairment.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
8.7
Source text (exact source wording)
8.7 Hepatic Impairment
Patients with moderate hepatic impairment do not require an adjustment in tamsulosin hydrochloride capsules dosage. Tamsulosin hydrochloride has not been studied in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].
Patients with moderate hepatic impairment do not require an adjustment in tamsulosin hydrochloride capsules dosage. Tamsulosin hydrochloride has not been studied in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].
Elderly
No overall differences in safety or effectiveness were seen between older and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
8.5
Source text (exact source wording)
8.5 Geriatric Use
Of the total number of subjects (1783) in clinical studies of tamsulosin, 36% were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and the other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].
Of the total number of subjects (1783) in clinical studies of tamsulosin, 36% were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and the other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].
Missed dose
Label
Take a missed dose as soon as you remember. If you miss a whole day, continue with your next dose on schedule. Do not take two doses at the same time. If you stop for several days, talk with your doctor before restarting; the label says to restart at 0.4 mg once daily.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
Patient Information; 2
Source text (exact source wording)
Patient Information: If you miss a dose of tamsulosin hydrochloride capsule, take it as soon as you remember. If you miss your dose for the whole day, continue with your next dose on your regular schedule. Do not take two doses at the same time. If you stop or forget to take tamsulosin hydrochloride capsules for several days, talk with your doctor before starting again.
Section 2: If tamsulosin hydrochloride capsules administration is discontinued or interrupted for several days at either the 0.4 mg or 0.8 mg dose, therapy should be started again with the 0.4 mg once-daily dose.
Section 2: If tamsulosin hydrochloride capsules administration is discontinued or interrupted for several days at either the 0.4 mg or 0.8 mg dose, therapy should be started again with the 0.4 mg once-daily dose.
Medlineplus
MedlinePlus gives similar advice and adds to call your doctor before restarting if treatment is interrupted for several days or longer.
Source
MedlinePlus Tamsulosin (https://medlineplus.gov/druginfo/meds/a698012.html), Last Revised - 12/15/2025
Section
MedlinePlus
Source text (exact source wording)
Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one. If you interrupt your treatment for several days or longer, call your doctor before restarting the medication, especially if you take more than one capsule of tamsulosin a day.
Overdose
If an overdose causes low blood pressure, supporting the heart and circulation is most important, and keeping the patient lying flat may help. Dialysis is unlikely to be of benefit. Call poison control at 1-800-222-1222; call 911 if the person has collapsed, had a seizure, has trouble breathing or cannot be awakened.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display); MedlinePlus Tamsulosin (https://medlineplus.gov/druginfo/meds/a698012.html), Last Revised - 12/15/2025
Section
10; MedlinePlus
Source text (exact source wording)
10 OVERDOSAGE
Should overdosage of tamsulosin hydrochloride capsules lead to hypotension [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)], support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, then administration of intravenous fluids should be considered. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that tamsulosin hydrochloride is 94% to 99% protein bound; therefore, dialysis is unlikely to be of benefit.
MedlinePlus: In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
Symptoms of overdose may include: dizziness, fainting; blurred vision; upset stomach; headache
Should overdosage of tamsulosin hydrochloride capsules lead to hypotension [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)], support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, then administration of intravenous fluids should be considered. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that tamsulosin hydrochloride is 94% to 99% protein bound; therefore, dialysis is unlikely to be of benefit.
MedlinePlus: In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
Symptoms of overdose may include: dizziness, fainting; blurred vision; upset stomach; headache
Storage
Store at 20° to 25°C (68° to 77°F) in a tight container and avoid excessive moisture. Short-term exposure from 59ºF (15ºC) to 86ºF (30ºC) is acceptable. This is the Rising label; other labelers can differ.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
16; Patient Information
Source text (exact source wording)
16 HOW SUPPLIED/STORAGE AND HANDLING
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Preserve in tight container. Avoid excessive moisture.
Keep tamsulosin hydrochloride capsules and all medicines out of reach of children.
Patient Information: Store tamsulosin hydrochloride capsules at room temperature 20° to 25°C (68° to 77°F). Short-term exposure to higher or lower temperatures [from 59ºF (15ºC) to 86ºF (30ºC)] is acceptable. Ask your doctor or pharmacist if you have any questions about storing your capsules.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Preserve in tight container. Avoid excessive moisture.
Keep tamsulosin hydrochloride capsules and all medicines out of reach of children.
Patient Information: Store tamsulosin hydrochloride capsules at room temperature 20° to 25°C (68° to 77°F). Short-term exposure to higher or lower temperatures [from 59ºF (15ºC) to 86ºF (30ºC)] is acceptable. Ask your doctor or pharmacist if you have any questions about storing your capsules.
Boxed warning
NONE (confirmed: the full printer-friendly label text, 67,615 characters, contains no BOXED WARNING heading and no 'WARNING:' box)Contraindications
Do not take tamsulosin if you are known to be allergic to it or any component of the capsule. Reactions have included skin rash, hives, itching, angioedema and breathing symptoms.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
4
Source text (exact source wording)
Tamsulosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules. Reactions have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [see Adverse Reactions (6.2)].
Warnings and precautions
Postural hypotension, dizziness and vertigo were seen more often with tamsulosin than placebo, and there is a potential risk of fainting. Patients starting treatment should avoid situations where injury could occur if they faint.
Heading
5.1 Orthostasis
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
5.1 Orthostasis
The signs and symptoms of orthostasis (postural hypotension, dizziness, and vertigo) were detected more frequently in tamsulosin hydrochloride capsule-treated patients than in placebo recipients. As with other alpha adrenergic blocking agents there is a potential risk of syncope [see Adverse Reactions (6.1)]. Patients beginning treatment with tamsulosin hydrochloride capsules should be cautioned to avoid situations in which injury could result should syncope occur.
The signs and symptoms of orthostasis (postural hypotension, dizziness, and vertigo) were detected more frequently in tamsulosin hydrochloride capsule-treated patients than in placebo recipients. As with other alpha adrenergic blocking agents there is a potential risk of syncope [see Adverse Reactions (6.1)]. Patients beginning treatment with tamsulosin hydrochloride capsules should be cautioned to avoid situations in which injury could result should syncope occur.
Tamsulosin is mainly broken down by CYP3A4 and CYP2D6. The 0.4 mg dose should not be used with strong CYP3A4 inhibitors or with other alpha adrenergic blocking agents. Use caution with moderate CYP3A4 inhibitors, strong or moderate CYP2D6 inhibitors, CYP2D6 poor metabolizers, cimetidine, PDE5 inhibitors and warfarin.
Heading
5.2 Drug Interactions
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
5.2 Drug Interactions
Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6. Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. Tamsulosin hydrochloride capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
Tamsulosin hydrochloride capsules should be used with caution in combination with cimetidine, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
Tamsulosin hydrochloride capsules should not be used in combination with other alpha adrenergic blocking agents [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].
Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].
Caution should be exercised with concomitant administration of warfarin and tamsulosin hydrochloride capsules [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)].
Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6. Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. Tamsulosin hydrochloride capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
Tamsulosin hydrochloride capsules should be used with caution in combination with cimetidine, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
Tamsulosin hydrochloride capsules should not be used in combination with other alpha adrenergic blocking agents [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].
Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].
Caution should be exercised with concomitant administration of warfarin and tamsulosin hydrochloride capsules [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)].
Rarely (probably less than 1 in 50,000 patients), tamsulosin has been linked to a persistent painful erection unrelated to sexual activity. If not treated properly it can lead to permanent impotence.
Heading
5.3 Priapism
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
5.3 Priapism
Rarely (probably less than 1 in 50,000 patients), tamsulosin, like other alpha1 antagonists, has been associated with priapism (persistent painful penile erection unrelated to sexual activity). Because this condition can lead to permanent impotence if not properly treated, patients must be advised about the seriousness of the condition.
Rarely (probably less than 1 in 50,000 patients), tamsulosin, like other alpha1 antagonists, has been associated with priapism (persistent painful penile erection unrelated to sexual activity). Because this condition can lead to permanent impotence if not properly treated, patients must be advised about the seriousness of the condition.
Prostate cancer and BPH often occur together, so patients should be screened for prostate cancer before treatment and at regular intervals afterwards.
Heading
5.4 Screening for Prostate Cancer
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
5.4 Screening for Prostate Cancer
Prostate cancer and BPH frequently co-exist; therefore, patients should be screened for the presence of prostate cancer prior to treatment with tamsulosin hydrochloride capsules and at regular intervals afterwards.
Prostate cancer and BPH frequently co-exist; therefore, patients should be screened for the presence of prostate cancer prior to treatment with tamsulosin hydrochloride capsules and at regular intervals afterwards.
Intraoperative Floppy Iris Syndrome (IFIS) has been seen during cataract and glaucoma surgery in some patients on or previously treated with alpha1 blockers. Starting tamsulosin in patients scheduled for cataract or glaucoma surgery is not recommended.
Heading
5.5 Intraoperative Floppy Iris Syndrome
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
5.5 Intraoperative Floppy Iris Syndrome
Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha1 blockers, including tamsulosin hydrochloride capsules [see Adverse Reactions (6.2)].
Most reports were in patients taking the alpha1 blocker when IFIS occurred, but in some cases, the alpha1 blocker had been stopped prior to surgery. In most of these cases, the alpha1 blocker had been stopped recently prior to surgery (2 to 14 days), but in a few cases, IFIS was reported after the patient had been off the alpha1 blocker for a longer period (5 weeks to 9 months). IFIS is a variant of small pupil syndrome and is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs and potential prolapse of the iris toward the phacoemulsification incisions. The patient’s ophthalmologist should be prepared for possible modifications to their surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.
IFIS may increase the risk of eye complications during and after the operation. The benefit of stopping alpha1 blocker therapy prior to cataract or glaucoma surgery has not been established. The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.
Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha1 blockers, including tamsulosin hydrochloride capsules [see Adverse Reactions (6.2)].
Most reports were in patients taking the alpha1 blocker when IFIS occurred, but in some cases, the alpha1 blocker had been stopped prior to surgery. In most of these cases, the alpha1 blocker had been stopped recently prior to surgery (2 to 14 days), but in a few cases, IFIS was reported after the patient had been off the alpha1 blocker for a longer period (5 weeks to 9 months). IFIS is a variant of small pupil syndrome and is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs and potential prolapse of the iris toward the phacoemulsification incisions. The patient’s ophthalmologist should be prepared for possible modifications to their surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.
IFIS may increase the risk of eye complications during and after the operation. The benefit of stopping alpha1 blocker therapy prior to cataract or glaucoma surgery has not been established. The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended.
In patients with sulfa allergy, allergic reaction to tamsulosin has been rarely reported. Caution is warranted if a patient reports a serious or life-threatening sulfa allergy.
Heading
5.6 Sulfa Allergy
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
5.6 Sulfa Allergy
In patients with sulfa allergy, allergic reaction to tamsulosin hydrochloride capsules has been rarely reported. If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules.
In patients with sulfa allergy, allergic reaction to tamsulosin hydrochloride capsules has been rarely reported. If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules.
Pregnancy and breastfeeding
Tamsulosin is not indicated for use in women. There are no adequate data on its use in pregnant women, and no adverse developmental effects were seen in rat or rabbit studies. There are no data on its presence in human milk or effects on a breastfed infant. MedlinePlus says it may decrease fertility in women and men.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display); MedlinePlus Tamsulosin (https://medlineplus.gov/druginfo/meds/a698012.html), Last Revised - 12/15/2025
Section
8.1, 8.2; MedlinePlus
Source text (exact source wording)
8.1 Pregnancy
Risk Summary
Tamsulosin hydrochloride is not indicated for use in women. There are no adequate data on the developmental risk associated with the use of tamsulosin hydrochloride in pregnant women. No adverse developmental effects were observed in animal studies in which tamsulosin hydrochloride was administered to rats or rabbits during the period of organogenesis (GD 7 to 17 in the rat and GD 6 to 18 in the rabbit) [see Data].
8.2 Lactation
Tamsulosin hydrochloride is not indicated for use in women. There are no data on the presence of tamsulosin hydrochloride in human milk, the effects of tamsulosin hydrochloride on the breastfed infant, or the effects of tamsulosin hydrochloride on milk production. Tamsulosin hydrochloride is present in the milk of lactating rats [see Data].
MedlinePlus: tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking tamsulosin, call your doctor. you should know that this medication may decrease fertility (ability to produce or have children) in women and men. This does not mean you can't get pregnant while taking tamsulosin and you should still use effective contraception.
Risk Summary
Tamsulosin hydrochloride is not indicated for use in women. There are no adequate data on the developmental risk associated with the use of tamsulosin hydrochloride in pregnant women. No adverse developmental effects were observed in animal studies in which tamsulosin hydrochloride was administered to rats or rabbits during the period of organogenesis (GD 7 to 17 in the rat and GD 6 to 18 in the rabbit) [see Data].
8.2 Lactation
Tamsulosin hydrochloride is not indicated for use in women. There are no data on the presence of tamsulosin hydrochloride in human milk, the effects of tamsulosin hydrochloride on the breastfed infant, or the effects of tamsulosin hydrochloride on milk production. Tamsulosin hydrochloride is present in the milk of lactating rats [see Data].
MedlinePlus: tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking tamsulosin, call your doctor. you should know that this medication may decrease fertility (ability to produce or have children) in women and men. This does not mean you can't get pregnant while taking tamsulosin and you should still use effective contraception.
Side effects
Common
The label's most common side effects (2% or more of patients and more often than placebo) were headache, dizziness, rhinitis, infection, abnormal ejaculation, asthenia, back pain, diarrhea, pharyngitis, chest pain, increased cough, sleepiness, nausea, sinusitis, insomnia, decreased libido, tooth disorder and blurred vision. For example, abnormal ejaculation was 8.4% on 0.4 mg and 18.1% on 0.8 mg versus 0.2% on placebo, and dizziness was 14.9% and 17.1% versus 10.1%.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
Highlights; 6.1 Table 1
Threshold
≥2% of patients and at a higher incidence than placebo
Source text (exact source wording)
Highlights: The most common adverse events (≥2% of patients and at a higher incidence than placebo) with the 0.4 mg dose or 0.8 mg dose were headache, dizziness, rhinitis, infection, abnormal ejaculation, asthenia, back pain, diarrhea, pharyngitis, chest pain, cough increased, somnolence, nausea, sinusitis, insomnia, libido decreased, tooth disorder, and blurred vision (6.1)
6.1: Table 1 summarizes the treatment-emergent adverse events that occurred in ≥2% of patients receiving either tamsulosin hydrochloride capsules 0.4 mg or 0.8 mg and at an incidence numerically higher than that in the placebo group during two 13-week U.S. trials (US92-03A and US93-01) conducted in 1487 men.
Table 1 Treatment-Emergent Adverse Events Occurring in ≥2% of Tamsulosin Hydrochloride Capsules or Placebo Patients in Two U.S. Short-Term Placebo-Controlled Clinical Studies (tamsulosin 0.4 mg n=502 / 0.8 mg n=492 / placebo n=493)
BODY AS WHOLE: Headache 97 (19.3%) / 104 (21.1%) / 99 (20.1%); Infection 45 (9%) / 53 (10.8%) / 37 (7.5%); Asthenia 39 (7.8%) / 42 (8.5%) / 27 (5.5%); Back pain 35 (7%) / 41 (8.3%) / 27 (5.5%); Chest pain 20 (4%) / 20 (4.1%) / 18 (3.7%)
NERVOUS SYSTEM: Dizziness 75 (14.9%) / 84 (17.1%) / 50 (10.1%); Somnolence 15 (3%) / 21 (4.3%) / 8 (1.6%); Insomnia 12 (2.4%) / 7 (1.4%) / 3 (0.6%); Libido decreased 5 (1%) / 10 (2%) / 6 (1.2%)
RESPIRATORY SYSTEM: Rhinitis 66 (13.1%) / 88 (17.9%) / 41 (8.3%); Pharyngitis 29 (5.8%) / 25 (5.1%) / 23 (4.7%); Cough increased 17 (3.4%) / 22 (4.5%) / 12 (2.4%); Sinusitis 11 (2.2%) / 18 (3.7%) / 8 (1.6%)
DIGESTIVE SYSTEM: Diarrhea 31 (6.2%) / 21 (4.3%) / 22 (4.5%); Nausea 13 (2.6%) / 19 (3.9%) / 16 (3.2%); Tooth disorder 6 (1.2%) / 10 (2%) / 7 (1.4%)
UROGENITAL SYSTEM: Abnormal ejaculation 42 (8.4%) / 89 (18.1%) / 1 (0.2%)
SPECIAL SENSES: Blurred vision 1 (0.2%) / 10 (2%) / 2 (0.4%)
6.1: Table 1 summarizes the treatment-emergent adverse events that occurred in ≥2% of patients receiving either tamsulosin hydrochloride capsules 0.4 mg or 0.8 mg and at an incidence numerically higher than that in the placebo group during two 13-week U.S. trials (US92-03A and US93-01) conducted in 1487 men.
Table 1 Treatment-Emergent Adverse Events Occurring in ≥2% of Tamsulosin Hydrochloride Capsules or Placebo Patients in Two U.S. Short-Term Placebo-Controlled Clinical Studies (tamsulosin 0.4 mg n=502 / 0.8 mg n=492 / placebo n=493)
BODY AS WHOLE: Headache 97 (19.3%) / 104 (21.1%) / 99 (20.1%); Infection 45 (9%) / 53 (10.8%) / 37 (7.5%); Asthenia 39 (7.8%) / 42 (8.5%) / 27 (5.5%); Back pain 35 (7%) / 41 (8.3%) / 27 (5.5%); Chest pain 20 (4%) / 20 (4.1%) / 18 (3.7%)
NERVOUS SYSTEM: Dizziness 75 (14.9%) / 84 (17.1%) / 50 (10.1%); Somnolence 15 (3%) / 21 (4.3%) / 8 (1.6%); Insomnia 12 (2.4%) / 7 (1.4%) / 3 (0.6%); Libido decreased 5 (1%) / 10 (2%) / 6 (1.2%)
RESPIRATORY SYSTEM: Rhinitis 66 (13.1%) / 88 (17.9%) / 41 (8.3%); Pharyngitis 29 (5.8%) / 25 (5.1%) / 23 (4.7%); Cough increased 17 (3.4%) / 22 (4.5%) / 12 (2.4%); Sinusitis 11 (2.2%) / 18 (3.7%) / 8 (1.6%)
DIGESTIVE SYSTEM: Diarrhea 31 (6.2%) / 21 (4.3%) / 22 (4.5%); Nausea 13 (2.6%) / 19 (3.9%) / 16 (3.2%); Tooth disorder 6 (1.2%) / 10 (2%) / 7 (1.4%)
UROGENITAL SYSTEM: Abnormal ejaculation 42 (8.4%) / 89 (18.1%) / 1 (0.2%)
SPECIAL SENSES: Blurred vision 1 (0.2%) / 10 (2%) / 2 (0.4%)
Less common
Symptomatic postural hypotension was reported by 0.2% of patients on 0.4 mg and 0.4% on 0.8 mg, and by no patients on placebo. Syncope was reported by 0.2% on 0.4 mg, 0.4% on 0.8 mg and 0.6% on placebo. The label's table lists no reactions below its 2% threshold.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
6.1 (orthostasis paragraph)
Source text (exact source wording)
Signs and Symptoms of Orthostasis: In the two U.S. studies, symptomatic postural hypotension was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group, and by no patients in the placebo group. Syncope was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group, and 0.6% of patients (3 of 493) in the placebo group.
Serious
Label
Serious items include fainting with low blood pressure on standing, priapism, eye-surgery complications (IFIS) and allergic-type reactions such as angioedema.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
5, 6.2
Source text (exact source wording)
5.1 orthostasis and potential syncope; 5.3 priapism; 5.5 IFIS; 5.6 sulfa allergy (see warnings above).
6.2 Postmarketing Experience: The following adverse reactions have been identified during post-approval use of tamsulosin hydrochloride capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Allergic-type reactions such as skin rash, urticaria, pruritus, angioedema, and respiratory symptoms have been reported with positive rechallenge in some cases. Priapism has been reported rarely. Infrequent reports of dyspnea, palpitations, hypotension, atrial fibrillation, arrhythmia, tachycardia, skin desquamation including reports of Stevens-Johnson syndrome, erythema multiforme, dermatitis exfoliative, constipation, vomiting, dry mouth, visual impairment, and epistaxis have been received during the postmarketing period.
During cataract and glaucoma surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in association with alpha1 blocker therapy [see Warnings and Precautions (5.5)].
6.2 Postmarketing Experience: The following adverse reactions have been identified during post-approval use of tamsulosin hydrochloride capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Allergic-type reactions such as skin rash, urticaria, pruritus, angioedema, and respiratory symptoms have been reported with positive rechallenge in some cases. Priapism has been reported rarely. Infrequent reports of dyspnea, palpitations, hypotension, atrial fibrillation, arrhythmia, tachycardia, skin desquamation including reports of Stevens-Johnson syndrome, erythema multiforme, dermatitis exfoliative, constipation, vomiting, dry mouth, visual impairment, and epistaxis have been received during the postmarketing period.
During cataract and glaucoma surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in association with alpha1 blocker therapy [see Warnings and Precautions (5.5)].
Medlineplus
MedlinePlus says to call your doctor right away for a painful erection that lasts for hours, rash, itching, hives, trouble breathing or shortness of breath, or swelling of the eyes, face, tongue, lips, throat, arms, hands, feet, ankles or lower legs.
Source
MedlinePlus Tamsulosin (https://medlineplus.gov/druginfo/meds/a698012.html), Last Revised - 12/15/2025
Section
MedlinePlus
Source text (exact source wording)
Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:
painful erection of the penis that lasts for hours
rash, itching, hives, difficulty breathing or shortness of breath
swelling of the eyes, face, tongue, lips, throat, arms, hands, feet, ankles, or lower legs
painful erection of the penis that lasts for hours
rash, itching, hives, difficulty breathing or shortness of breath
swelling of the eyes, face, tongue, lips, throat, arms, hands, feet, ankles, or lower legs
Led to discontinuation
Stopping because of abnormal ejaculation was dose-dependent: 8 of 492 patients (1.6%) in the 0.8 mg group and none in the 0.4 mg or placebo groups.
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
6.1
Source text (exact source wording)
Abnormal Ejaculation: Abnormal ejaculation includes ejaculation failure, ejaculation disorder, retrograde ejaculation, and ejaculation decrease. As shown in Table 1, abnormal ejaculation was associated with tamsulosin hydrochloride capsules administration and was dose-related in the U.S. studies. Withdrawal from these clinical studies of tamsulosin hydrochloride capsules because of abnormal ejaculation was also dose-dependent, with 8 of 492 patients (1.6%) in the 0.8 mg group and no patients in the 0.4 mg or placebo groups discontinuing treatment due to abnormal ejaculation.
Interactions
Drugs
The 0.4 mg capsule should not be used with strong CYP3A4 inhibitors such as ketoconazole, which raised tamsulosin Cmax and AUC by a factor of 2.2 and 2.8.
Name
Strong CYP3A4 inhibitors (e.g., ketoconazole)
Section
2; 5.2; 7.1
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Warnings and Precautions (5.2)]. Concomitant treatment with ketoconazole (a strong inhibitor of CYP3A4) resulted in an increase in the Cmax and AUC of tamsulosin by a factor of 2.2 and 2.8, respectively
Use caution with moderate CYP3A4 inhibitors and with strong or moderate CYP2D6 inhibitors, and in CYP2D6 poor metabolizers, particularly at doses above 0.4 mg. Paroxetine raised tamsulosin Cmax and AUC by a factor of 1.3 and 1.6.
Name
Moderate CYP3A4 inhibitors (e.g., erythromycin); CYP2D6 inhibitors (e.g., paroxetine, terbinafine); CYP2D6 poor metabolizers
Section
5.2; 7.1
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
Tamsulosin hydrochloride capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers particularly at a dose higher than 0.4 mg (e.g., 0.8 mg). Concomitant treatment with paroxetine (a strong inhibitor of CYP2D6) resulted in an increase in the Cmax and AUC of tamsulosin by a factor of 1.3 and 1.6, respectively
Cimetidine caused a significant decrease (26%) in tamsulosin clearance and a moderate increase (44%) in AUC. Use caution, especially above 0.4 mg.
Name
Cimetidine
Section
5.2; 7.1
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
Cimetidine
Treatment with cimetidine resulted in a significant decrease (26%) in the clearance of tamsulosin hydrochloride, which resulted in a moderate increase in tamsulosin hydrochloride AUC (44%) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]. (5.2: Tamsulosin hydrochloride capsules should be used with caution in combination with cimetidine, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg))
Treatment with cimetidine resulted in a significant decrease (26%) in the clearance of tamsulosin hydrochloride, which resulted in a moderate increase in tamsulosin hydrochloride AUC (44%) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]. (5.2: Tamsulosin hydrochloride capsules should be used with caution in combination with cimetidine, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg))
Tamsulosin should not be used with other alpha adrenergic blocking agents; interactions may be expected.
Name
Other alpha adrenergic blocking agents
Section
5.2; 7.2
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
7.2 Other Alpha Adrenergic Blocking Agents
The pharmacokinetic and pharmacodynamic interactions between tamsulosin hydrochloride capsules and other alpha adrenergic blocking agents have not been determined; however, interactions between tamsulosin hydrochloride capsules and other alpha adrenergic blocking agents may be expected [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
The pharmacokinetic and pharmacodynamic interactions between tamsulosin hydrochloride capsules and other alpha adrenergic blocking agents have not been determined; however, interactions between tamsulosin hydrochloride capsules and other alpha adrenergic blocking agents may be expected [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
Both are vasodilators that can lower blood pressure; using them together can potentially cause symptomatic hypotension.
Name
PDE5 inhibitors
Section
5.2; 7.3
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
7.3 PDE5 Inhibitors
Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
A definitive interaction study was not conducted and results are inconclusive. Use caution when combining with warfarin.
Name
Warfarin
Section
5.2; 7.4
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
7.4 Warfarin
A definitive drug-drug interaction study between tamsulosin hydrochloride and warfarin was not conducted. Results from limited in vitro and in vivo studies are inconclusive. Caution should be exercised with concomitant administration of warfarin and tamsulosin hydrochloride capsules [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
A definitive drug-drug interaction study between tamsulosin hydrochloride and warfarin was not conducted. Results from limited in vitro and in vivo studies are inconclusive. Caution should be exercised with concomitant administration of warfarin and tamsulosin hydrochloride capsules [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
No dosage adjustment is needed with nifedipine, atenolol, enalapril, digoxin or theophylline. Furosemide produced an 11% to 12% reduction in tamsulosin Cmax and AUC, expected to be clinically insignificant.
Name
Nifedipine, atenolol, enalapril, digoxin, theophylline, furosemide
Section
7.5-7.7
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
7.5 Nifedipine, Atenolol, Enalapril
Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see Clinical Pharmacology (12.3)].
7.6 Digoxin and Theophylline
Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology (12.3)].
7.7 Furosemide
Tamsulosin hydrochloride capsules had no effect on the pharmacodynamics (excretion of electrolytes) of furosemide. While furosemide produced an 11% to 12% reduction in tamsulosin hydrochloride Cmax and AUC, these changes are expected to be clinically insignificant and do not require adjustment of the tamsulosin hydrochloride capsules dosage [see Clinical Pharmacology (12.3)].
Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see Clinical Pharmacology (12.3)].
7.6 Digoxin and Theophylline
Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology (12.3)].
7.7 Furosemide
Tamsulosin hydrochloride capsules had no effect on the pharmacodynamics (excretion of electrolytes) of furosemide. While furosemide produced an 11% to 12% reduction in tamsulosin hydrochloride Cmax and AUC, these changes are expected to be clinically insignificant and do not require adjustment of the tamsulosin hydrochloride capsules dosage [see Clinical Pharmacology (12.3)].
Food and alcohol
Take tamsulosin about one-half hour after the same meal each day.
Name
Meal timing
Section
2
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Source text (exact source wording)
It should be administered approximately one-half hour following the same meal each day.
No statement on alcohol was found in the sources.
Name
Alcohol
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Other
MedlinePlus lists cimetidine as a nonprescription product that may interact with tamsulosin.
Name
Cimetidine (OTC)
Section
MedlinePlus
Source
MedlinePlus Tamsulosin (https://medlineplus.gov/druginfo/meds/a698012.html), Last Revised - 12/15/2025
Source text (exact source wording)
the following nonprescription product may interact with tamsulosin: cimetidine.
Patient tips
Label medication guide
Take it exactly as prescribed, about 30 minutes after the same meal each day, and do not crush, chew or open the capsule. Avoid driving or dangerous activities until you know how it affects you, and change positions slowly. Tell your surgeon if you take or have taken tamsulosin before cataract or glaucoma surgery. Get medical help right away for a painful erection that will not go away or serious allergic reactions.
Source
Patient Information in DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Section
Patient Information
Source text (exact source wording)
How should I take tamsulosin hydrochloride capsules?
Take tamsulosin hydrochloride capsules exactly as prescribed by your doctor.
Do not crush, chew, or open tamsulosin hydrochloride capsules.
Take tamsulosin hydrochloride capsules one time each day, about 30 minutes after the same meal each day. For example, you may take tamsulosin hydrochloride capsules 30 minutes after dinner each day.
If you miss a dose of tamsulosin hydrochloride capsule, take it as soon as you remember. If you miss your dose for the whole day, continue with your next dose on your regular schedule. Do not take two doses at the same time.
If you stop or forget to take tamsulosin hydrochloride capsules for several days, talk with your doctor before starting again.
If you take more tamsulosin hydrochloride capsules than prescribed, call your doctor right away.
What should I avoid while taking tamsulosin hydrochloride capsules?
Avoid driving, operating machinery, or other dangerous activities, until you know how tamsulosin hydrochloride capsules affect you. Tamsulosin hydrochloride capsules may cause a sudden drop in blood pressure upon standing, especially after the first dose or when changing doses.
What should I tell my doctor before using tamsulosin hydrochloride capsules?
Before taking tamsulosin hydrochloride capsules, tell your doctor about all your medical conditions, including: any kidney or liver problems. any history of low blood pressure. any allergies to sulfa or any other medicines. if you are planning to have cataract or glaucoma surgery.
Tell your doctor about all the medicines you take, including: any prescription medicines, including blood pressure medicines. any non-prescription medicines, including vitamins and herbal supplements.
Some of your other medicines may affect the way tamsulosin hydrochloride capsules work. Especially tell your doctor if you take a medicine for high blood pressure. You should not take tamsulosin hydrochloride capsules if you are already taking certain blood pressure medicines.
What are the possible side effects of tamsulosin hydrochloride capsules?
Possible side effects of tamsulosin hydrochloride capsules may include:
Decreased blood pressure when changing positions. Tamsulosin hydrochloride capsules may cause a sudden drop in blood pressure upon standing, especially after the first dose or when changing doses. Symptoms may include: fainting; dizziness; lightheadedness
Change positions slowly from lying down to sitting up or from a sitting to a standing position until you learn how you react to tamsulosin hydrochloride capsules. If you begin to feel dizzy, sit or lie down until you feel better. If the symptoms are severe or do not improve, call your doctor.
Allergic reactions. Make your doctor aware of any allergic reactions you may experience while taking tamsulosin hydrochloride capsules. Allergic reactions may include: rash; itching; hives
Rare and more serious allergic reactions may also occur. Get medical help right away if you have any of the following reactions: swelling of face, tongue, or throat; difficulty breathing; blistering of the skin
A painful erection that will not go away. Tamsulosin hydrochloride capsules can cause a painful erection (priapism), which cannot be relieved by having sex. If this happens, get medical help right away. If priapism is not treated, you may not be able to get an erection in the future.
Eye problems during cataract or glaucoma surgery. During cataract or glaucoma surgery, a condition called intraoperative floppy iris syndrome (IFIS) can happen if you take or have taken tamsulosin hydrochloride capsules. If you need to have cataract or glaucoma surgery, be sure to tell your surgeon if you take or have taken tamsulosin hydrochloride capsules.
Common side effects of tamsulosin hydrochloride capsules may include: runny nose; dizziness; decreased semen
Take tamsulosin hydrochloride capsules exactly as prescribed by your doctor.
Do not crush, chew, or open tamsulosin hydrochloride capsules.
Take tamsulosin hydrochloride capsules one time each day, about 30 minutes after the same meal each day. For example, you may take tamsulosin hydrochloride capsules 30 minutes after dinner each day.
If you miss a dose of tamsulosin hydrochloride capsule, take it as soon as you remember. If you miss your dose for the whole day, continue with your next dose on your regular schedule. Do not take two doses at the same time.
If you stop or forget to take tamsulosin hydrochloride capsules for several days, talk with your doctor before starting again.
If you take more tamsulosin hydrochloride capsules than prescribed, call your doctor right away.
What should I avoid while taking tamsulosin hydrochloride capsules?
Avoid driving, operating machinery, or other dangerous activities, until you know how tamsulosin hydrochloride capsules affect you. Tamsulosin hydrochloride capsules may cause a sudden drop in blood pressure upon standing, especially after the first dose or when changing doses.
What should I tell my doctor before using tamsulosin hydrochloride capsules?
Before taking tamsulosin hydrochloride capsules, tell your doctor about all your medical conditions, including: any kidney or liver problems. any history of low blood pressure. any allergies to sulfa or any other medicines. if you are planning to have cataract or glaucoma surgery.
Tell your doctor about all the medicines you take, including: any prescription medicines, including blood pressure medicines. any non-prescription medicines, including vitamins and herbal supplements.
Some of your other medicines may affect the way tamsulosin hydrochloride capsules work. Especially tell your doctor if you take a medicine for high blood pressure. You should not take tamsulosin hydrochloride capsules if you are already taking certain blood pressure medicines.
What are the possible side effects of tamsulosin hydrochloride capsules?
Possible side effects of tamsulosin hydrochloride capsules may include:
Decreased blood pressure when changing positions. Tamsulosin hydrochloride capsules may cause a sudden drop in blood pressure upon standing, especially after the first dose or when changing doses. Symptoms may include: fainting; dizziness; lightheadedness
Change positions slowly from lying down to sitting up or from a sitting to a standing position until you learn how you react to tamsulosin hydrochloride capsules. If you begin to feel dizzy, sit or lie down until you feel better. If the symptoms are severe or do not improve, call your doctor.
Allergic reactions. Make your doctor aware of any allergic reactions you may experience while taking tamsulosin hydrochloride capsules. Allergic reactions may include: rash; itching; hives
Rare and more serious allergic reactions may also occur. Get medical help right away if you have any of the following reactions: swelling of face, tongue, or throat; difficulty breathing; blistering of the skin
A painful erection that will not go away. Tamsulosin hydrochloride capsules can cause a painful erection (priapism), which cannot be relieved by having sex. If this happens, get medical help right away. If priapism is not treated, you may not be able to get an erection in the future.
Eye problems during cataract or glaucoma surgery. During cataract or glaucoma surgery, a condition called intraoperative floppy iris syndrome (IFIS) can happen if you take or have taken tamsulosin hydrochloride capsules. If you need to have cataract or glaucoma surgery, be sure to tell your surgeon if you take or have taken tamsulosin hydrochloride capsules.
Common side effects of tamsulosin hydrochloride capsules may include: runny nose; dizziness; decreased semen
Medlineplus
MedlinePlus says to swallow the capsules whole, keep taking them even if you feel well, tell your doctor about eye surgery, and get up slowly to avoid dizziness and fainting.
Source
MedlinePlus Tamsulosin (https://medlineplus.gov/druginfo/meds/a698012.html), Last Revised - 12/15/2025
Section
MedlinePlus
Source text (exact source wording)
Tamsulosin comes as a capsule to take by mouth. Take once a day 30 minutes after a meal. Take around the same time every day.
Take tamsulosin exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow tamsulosin capsules whole; do not split, chew, crush, or open them.
Your doctor will probably start you on a low dose of tamsulosin and may increase your dose after 2 to 4 weeks.
Tamsulosin may help control your condition, but it will not cure it. Continue to take tamsulosin even if you feel well. Do not stop taking tamsulosin without talking to your doctor.
tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking tamsulosin, call your doctor.
you should know that this medication may decrease fertility (ability to produce or have children) in women and men. This does not mean you can't get pregnant while taking tamsulosin and you should still use effective contraception.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking tamsulosin. If you need to have eye surgery at any time during or after your treatment, be sure to tell your doctor that you are taking or have taken tamsulosin.
you should know that this medication may make you drowsy or dizzy. Do not drive a car, operate machinery, or perform dangerous tasks until you know how this medication affects you.
you should know that tamsulosin may cause dizziness, lightheadedness, a spinning sensation, and fainting, especially when you get up too quickly from a lying position.
Take tamsulosin exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow tamsulosin capsules whole; do not split, chew, crush, or open them.
Your doctor will probably start you on a low dose of tamsulosin and may increase your dose after 2 to 4 weeks.
Tamsulosin may help control your condition, but it will not cure it. Continue to take tamsulosin even if you feel well. Do not stop taking tamsulosin without talking to your doctor.
tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking tamsulosin, call your doctor.
you should know that this medication may decrease fertility (ability to produce or have children) in women and men. This does not mean you can't get pregnant while taking tamsulosin and you should still use effective contraception.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking tamsulosin. If you need to have eye surgery at any time during or after your treatment, be sure to tell your doctor that you are taking or have taken tamsulosin.
you should know that this medication may make you drowsy or dizzy. Do not drive a car, operate machinery, or perform dangerous tasks until you know how this medication affects you.
you should know that tamsulosin may cause dizziness, lightheadedness, a spinning sensation, and fainting, especially when you get up too quickly from a lying position.
When to call doctor
See the Patient Information 'get medical help right away' list and the MedlinePlus serious side effects list above.
Alternatives
Class source
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display (Highlights: alpha1 adrenoceptor antagonist); https://medlineplus.gov/druginfo/meds/a698012.html (alpha blockers)
Indication source
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display section 1 (BPH)
Note
No recommendation of one over another.
Frequently asked questions
Question
What is tamsulosin used for?
Answer
Tamsulosin treats the signs and symptoms of benign prostatic hyperplasia (BPH). It is not indicated for the treatment of hypertension.
Source section
1
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Question
How do I take tamsulosin?
Answer
The recommended dose is 0.4 mg once daily, about one-half hour after the same meal each day. Do not crush, chew or open the capsule. If there is no response after 2 to 4 weeks, the dose can be increased to 0.8 mg once daily.
Source section
2
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Question
What if I miss a dose?
Answer
Take it as soon as you remember. If you miss your dose for the whole day, continue with your next dose on your regular schedule. Do not take two doses at the same time. If you stop for several days, talk with your doctor before restarting.
Source section
Patient Information
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Question
What are the common side effects?
Answer
The most common side effects (2% or more of patients and more often than placebo) were headache, dizziness, rhinitis, infection, abnormal ejaculation, asthenia, back pain, diarrhea, pharyngitis, chest pain, increased cough, sleepiness, nausea, sinusitis, insomnia, decreased libido, tooth disorder and blurred vision.
Source section
Highlights; 6.1
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Question
Can tamsulosin make me dizzy or faint?
Answer
Yes. Postural hypotension, dizziness and vertigo were seen more often than with placebo. Avoid driving, operating machinery or other dangerous activities until you know how it affects you, and change positions slowly.
Source section
5.1; Patient Information
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Question
What should I tell my eye surgeon?
Answer
Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in some patients on or previously treated with alpha1 blockers. Tell your surgeon if you take or have taken tamsulosin.
Source section
5.5; Patient Information
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Question
What should I not combine with tamsulosin?
Answer
The 0.4 mg capsule should not be used with strong CYP3A4 inhibitors such as ketoconazole or with other alpha adrenergic blocking agents. Use caution with PDE5 inhibitors, warfarin, cimetidine and certain CYP2D6 or moderate CYP3A4 inhibitors.
Source section
5.2; 7
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Question
Is tamsulosin for women or children?
Answer
No. The label says tamsulosin is not indicated for use in women or in pediatric populations.
Source section
8.1; 8.4
Source
DailyMed printer-friendly label Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.), set ID a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a, Revised: 12/2025 (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a&type=display)
Question
Should I stop tamsulosin when I feel better?
Answer
MedlinePlus says to continue taking tamsulosin even if you feel well and not to stop without talking to your doctor.
Source section
MedlinePlus
Source
MedlinePlus Tamsulosin (https://medlineplus.gov/druginfo/meds/a698012.html), Last Revised - 12/15/2025
Sources
- DailyMed printer-friendly label, Tamsulosin Hydrochloride Capsules (Rising Pharma Holdings, Inc.) - CHOSEN
Set id: a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a · Label effective or revised date: Revised: 12/2025 · Dailymed version date: Jan 15, 2026 (DailyMed list publish date; the page also shows a trailing 'Revised: 1/2026' after the package data) · Fetched at: 2026-11-03 · Sections used: Highlights, 1-8, 10, 12.1, 16, Patient Information, package data (read from full text via get_page_text) - MedlinePlus Tamsulosin
Label effective or revised date: Last Revised - 12/15/2025 · Fetched at: 2026-11-03 · Sections used: full page - ALTERNATE 1: Tamsulosin capsules, Amneal Pharmaceuticals of New York LLC
Set id: c3ae55dd-6a0e-4f3a-82b6-2448e0545550 · Label effective or revised date: Revised: 3/2025 (from the earlier header read; not re-read from printer-friendly text) · Dailymed version date: Apr 21, 2025 · Fetched at: 2026-11-02 · Sections used: header only - ALTERNATE 2: Tamsulosin capsules, Synthon Pharmaceuticals, Inc.
Set id: 13a5032d-0be1-4001-916e-459f0b1a051d · Label effective or revised date: Revised: 2/2025 (from the earlier header read; not re-read from printer-friendly text) · Dailymed version date: Dec 02, 2025 · Fetched at: 2026-11-02 · Sections used: header only - openFDA Drugs@FDA data, Flomax search
Fetched at: 2026-11-03 · Sections used: returned NOT_FOUND (no matches)
Information is taken from the cited sources and is for general reference only. It is not medical advice. Report side effects to FDA MedWatch at 1-800-FDA-1088. For a poison emergency call 1-800-222-1222. See prices for this drug